Tigecycline Soft Tissue Penetration in Obese and Non-obese Surgical Patients Determined by Using In Vivo Microdialysis-Reference-Cited by-同舟云学术

Tigecycline Soft Tissue Penetration in Obese and Non-obese Surgical Patients Determined by Using In Vivo Microdialysis

Published:2022-08-09 Issue:5 Volume:47 Page:749-755
ISSN:0378-7966
Container-title:European Journal of Drug Metabolism and Pharmacokinetics
language:en
Short-container-title:Eur J Drug Metab Pharmacokinet

Author:

Dorn Christoph^ORCID,Petroff David,Kratzer Alexander,Kees Frieder,Kloft Charlotte,Zeitlinger Markus,Wrigge Hermann,Simon Philipp

Funder

Bundesministerium für Bildung und Forschung

Universität Regensburg

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s13318-022-00789-2.pdf

Reference22 articles.

1. Alobaid AS, Hites M, Lipman J, Taccone FS, Roberts JA. Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: a structured review. Int J Antimicrob Agents. 2016;47:259–68.

2. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;49:71–87.

3. Pai MP. Antimicrobial dosing in specific populations and novel clinical methodologies: obesity. Clin Pharmacol Ther. 2021;109:942–51.

4. Barbour A, Schmidt S, Ma B, Schiefelbein L, Rand KH, Burkhardt O, et al. Clinical pharmacokinetics and pharmacodynamics of tigecycline. Clin Pharmacokinet. 2009;48:575–84.

5. Wyeth Pharmaceuticals LLC. TYGACIL® (tigecycline) for injection, for intravenous use, Prescribing information [Internet]. 2021. Available from: https://labeling.pfizer.com/ShowLabeling.aspx?id=491.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current recommendations for antibiotic dosing in obese patients;Vnitřní lékařství;2024-09-04

2. Penetration of Antibiotics into Subcutaneous and Intramuscular Interstitial Fluid: A Meta-Analysis of Microdialysis Studies in Adults;Clinical Pharmacokinetics;2024-07

3. Updated antimicrobial dosing recommendations for obese patients;Antimicrobial Agents and Chemotherapy;2024-05-02

4. Pharmacokinetic/pharmacodynamic evaluation of tigecycline dosing in a hollow fiber infection model against clinical bla-KPC producing Klebsiella Pneumoniae isolates;Diagnostic Microbiology and Infectious Disease;2024-02

5. Emergence of high-level tigecycline resistance due to the amplification of a tet(A) gene variant in clinical carbapenem-resistant Klebsiella pneumoniae;Clinical Microbiology and Infection;2023-11